05Jan 2023
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Nirmatrelvir–ritonavir has been authorized for emergency use by many countries to treat coronavirus disease 2019 (Covid-19). However, the supply falls short of the global demand, which creates a need for more options. VV116 is an oral antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among adults with mild-to-moderate COVID-19 at risk for progression, VV116 was non-inferior to nirmatrelvir/ritonavir concerning the time to sustained clinical recovery, with fewer safety concerns.

  • #family health

Like

Save

Share